Compare Allegion PLC (ALLE) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Crispr Therapeutics AG — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Crispr Therapeutics AG trades at $53.2 (market cap $5.25B). The key difference: Allegion PLC is far larger — about 2.2× Crispr Therapeutics AG's market cap, and Allegion PLC pays a 1.55% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ALLE | CRSP | |
|---|---|---|
Market Cap | $11.74B | $5.25B |
Sector | Industrials | Health |
52-Week High | $179.77 | $76.78 |
52-Week Low | $125.65 | $44.34 |
Enterprise Value | $13.46B | $3.60B |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
CRISPR Therapeutics (CRSP) trades at $53.35, down 5.31% on the day, with technical indicators showing a bullish trend but mixed earnings performance. The company maintains strong analyst support with a $74.50 consensus price target, despite negative profitability metrics and recent quarterly misses. Recent FDA pediatric approval for Casgevy expands its market potential, though cash flow remains challenged by high operational costs.
Outlook is cautiously optimistic driven by gene-editing leadership and clinical catalysts, but investment carries high risk due to persistent losses, volatile cash flows, and competitive pressures. Upside depends on successful commercialization and pipeline execution, while downside risks include funding needs and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
